Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$136.63 USD
-1.84 (-1.33%)
Updated Oct 10, 2025 04:00 PM ET
After-Market: $136.57 -0.06 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NBIX 136.63 -1.84(-1.33%)
Will NBIX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
GRFS or NBIX: Which Is the Better Value Stock Right Now?
GRFS or NBIX: Which Is the Better Value Stock Right Now?
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Other News for NBIX
Is NBIX building bearish momentum? Fell Below 50 Day Moving Average shows up after declining 1.33%
Is NBIX likely to continue higher? Directional Movement Crossover Bullish shows up after sliding 0.44%
Neurocrine price target raised to $195 from $188 at UBS
Neurocrine price target raised by $7 at UBS, here's why
Is NBIX poised for gains? Crossed Above 50 Day Moving Average shows up after rising 1.52%